[18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies.
Alzheimer's disease (AD) is becoming an increasingly important public health problem. The clinical diagnosis of AD continues to be problematic and costly. [18F]-fluorodeoxyglucose-position emission tomography (FDG-PET) can assist with the diagnosis of AD at an early stage. The utility of FDG-PET in AD may also be extremely useful in the future when objective physiologic monitoring of drug effects and therapy are required.
Hoffman
J M
JM
Department of Radiological Sciences, University of California, Los Angeles.
Guze
B H
BH
Baxter
L R
LR
Mazziotta
J C
JC
Phelps
M E
ME
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000378:metabolism; D002648:Child; D003837:Deoxy Sugars; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging
D003837:Deoxy Sugars; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose